SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Free Report) - Investment analysts at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for SBC Medical Group in a research note issued on Monday, March 3rd. Zacks Small Cap analyst M. Marin forecasts that the company will post earnings per share of $0.61 for the year. The consensus estimate for SBC Medical Group's current full-year earnings is $5.02 per share. Zacks Small Cap also issued estimates for SBC Medical Group's Q4 2024 earnings at $0.19 EPS and FY2025 earnings at $0.69 EPS.
SBC Medical Group Stock Performance
SBC stock traded up $0.19 during midday trading on Wednesday, reaching $3.28. The company's stock had a trading volume of 67,818 shares, compared to its average volume of 63,479. SBC Medical Group has a 1 year low of $2.62 and a 1 year high of $12.50. The company's fifty day moving average price is $4.98. The company has a quick ratio of 2.76, a current ratio of 2.79 and a debt-to-equity ratio of 0.06.
SBC Medical Group Company Profile
(
Get Free Report)
SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand.
Featured Stories
Before you consider SBC Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SBC Medical Group wasn't on the list.
While SBC Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
